High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.

Abstract

Gemtuzumab ozogamicin (GO), an anti-CD33 immunoconjugate, was combined with high dose cytarabine (HiDAC; cytarabine 3g/m(2) over 3h daily for 5 days) for adults with relapsed or refractory AML. HiDAC plus GO 9mg/m(2) on day 7 and 4.5mg/m(2) on day 14 was not tolerated, but HiDAC followed by GO 9mg/m(2) on day 7 was safe: 12/37 (32%) patients with relapsed AML achieved complete remission. Median overall survival was 8.9 months. No grade 4 hepatic veno-occlusive disease was observed. This regimen merits further study, both in this setting and as a remission consolidation therapy.

DOI: 10.1016/j.leukres.2010.07.017
020040020132014201520162017
Citations per Year

512 Citations

Semantic Scholar estimates that this publication has 512 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Stone2011HighDC, title={High dose cytarabine plus gemtuzumab ozogamicin for patients with relapsed or refractory acute myeloid leukemia: Cancer and Leukemia Group B study 19902.}, author={Richard M Stone and Barry Kurt Moser and Ben L. Sanford and Philip P. Schulman and Jonathan E Kolitz and Steven L. Allen and Wendy A. Stock and Ilene A. Galinsky and Ravi Vij and Guido Marcucci and David D. Hurd and Richard A. Larson}, journal={Leukemia research}, year={2011}, volume={35 3}, pages={329-33} }